Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in advanced cholangiocarcinoma
NCT03656536Phase 3Terminated
- Sponsor
- Incyte
- Start
- Jun 2019
- Primary completion
- Jul 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of pemigatinib in cholangiocarcinoma (CCA) (2 arms), sponsored by Incyte. Primary endpoint: Progression-free Survival up to 1496 days. Started Jun 2019; status: terminated.
02
Drugs
pemigatinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT03656536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656536.